Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Stock Information for ATAI Life Sciences N.V.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ATAI Life Sciences N.V.

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder
Cybin to Participate at the 28th Annual Milken Institute Global Conference
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs
Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.